Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group

The American Journal of Cardiology
G V NaccarelliP Coumel

Abstract

In order to compare the efficacy and long-term tolerability of flecainide acetate versus quinidine, 239 patients with paroxysmal atrial fibrillation were prospectively treated with flecainide (n = 122) or quinidine (n = 117) in an open-label, randomized trial. All patients were followed for 1 year after initiation of therapy unless their antiarrhythmic drug was discontinued due to an inadequate therapeutic response or intolerable side effects. Although both drugs were equally effective in adequately controlling recurrences of atrial fibrillation (difference, p = 0.282; not significant), fewer flecainide patients had to have their therapy discontinued due to adverse experiences (p = 0.012). Based on both endpoints (efficacy and tolerability), an estimated 70.5% of flecainide versus 55.4% of quinidine patients would remain effectively treated at the end of 1 year on therapy (p < or = 0.007). The findings of this prospective study suggest that in the treatment of paroxysmal atrial fibrillation (1) flecainide and quinidine are equally effective in the acceptable suppression of symptomatic paroxysmal atrial fibrillation; (2) flecainide is better tolerated than quinidine and is less likely to be discontinued due to adverse effects; a...Continue Reading

References

May 7, 1992·The New England Journal of Medicine·E L Pritchett
Aug 25, 1988·The American Journal of Cardiology·J L AndersonP A Fredell

❮ Previous
Next ❯

Citations

Feb 28, 2002·Lancet·Nicholas S PetersVias Markides
Sep 23, 2014·Current Problems in Cardiology·Mitchell A Psotka, Byron K Lee
Jan 29, 2005·BMJ : British Medical Journal·M Bilal IqbalMarcus Flather
Nov 18, 1997·Journal of Cardiovascular Electrophysiology·L I Ganz, E M Antman
Sep 28, 2005·Nature Clinical Practice. Cardiovascular Medicine·Gemma Pelargonio, Eric N Prystowsky
Aug 10, 2002·Current Cardiology Reports·Gerald V NaccarelliJerry Luck
Aug 23, 2000·Current Cardiology Reports·E Kongsgaard, H Aass
Nov 30, 2010·Herzschrittmachertherapie & Elektrophysiologie·C PottL Eckardt
Jan 1, 1998·The New England Journal of Medicine·A A Grace, A J Camm
Jul 28, 2004·Circulation Journal : Official Journal of the Japanese Circulation Society·Takashi KomatsuKen Okumura
Feb 27, 2007·Circulation Journal : Official Journal of the Japanese Circulation Society·Hirotsugu AtarashiUNKNOWN Flecainide Atrial Fibrillation Investigators
Jul 27, 2007·Circulation Journal : Official Journal of the Japanese Circulation Society·Kohei MiyajiTohru Ohe
Nov 4, 2016·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Alessandro CapucciFederico Guerra
Feb 19, 2011·The Canadian Journal of Cardiology·Anne M GillisUNKNOWN CCS Atrial Fibrillation Guidelines Committee
Jun 7, 2008·Heart Rhythm : the Official Journal of the Heart Rhythm Society·Andrew E EpsteinUNKNOWN Society of Thoracic Surgeons
Mar 10, 2004·Journal of Cardiovascular Electrophysiology·Douglas L PackerThomas M Munger
May 8, 2009·Annals of Noninvasive Electrocardiology : the Official Journal of the International Society for Holter and Noninvasive Electrocardiology, Inc·Bernhard SchwaabHendrik Bonnemeier
Feb 18, 2011·Expert Opinion on Pharmacotherapy·Alessandro Marinelli, Alessandro Capucci
Mar 16, 2001·Expert Opinion on Pharmacotherapy·J Nemec, W K Shen
Jun 7, 2005·Expert Opinion on Emerging Drugs·Redi PeciniChristian Torp-Pedersen
Jan 9, 2013·Expert Opinion on Pharmacotherapy·Stavros ApostolakisPaulus Kirchhof
Apr 15, 2015·European Journal of Clinical Pharmacology·Juan TamargoPhillipe Mabo
Feb 27, 2016·Expert Opinion on Therapeutic Targets·Jules C HancoxDierk Thomas
Feb 16, 2005·Current Problems in Cardiology·Ken W LeeUNKNOWN University of Califoirnia-San Francisco, San Francisco, CA, USA
Nov 6, 2002·The American Journal of Geriatric Cardiology·Mark Dayer, Suzanna M C Hardman
May 30, 1998·Pacing and Clinical Electrophysiology : PACE·J KassotisJ A Reiffel
Nov 18, 2010·Circulation. Cardiovascular Quality and Outcomes·Daniel B Kramer, Mark E Josephson
Sep 12, 2009·Pacing and Clinical Electrophysiology : PACE·Juan ShuGan-Xin Yan
Sep 4, 2004·PharmacoEconomics·M P TengD P Melby
Apr 22, 2006·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Michele GuliziaAndrea Grammatico

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.